ORIGINAL PAPER



Green synthesis and antibacterial activity of chalcogenoesters

Rafael S. da Silva¹ · Guerino B. Junior² · Letiére C. Soares³ · Fernanda H. da Rosa¹ · Bruno B. Ravanello¹ · Luciano Dornelles¹ · Victor dos S. Barboza⁴ · Rodrigo de A. Vaucher⁴ · Roberto C. V. Santos² · Bernardo Baldisserotto² · Oscar E. D. Rodrigues¹

Received: 2 December 2019 / Accepted: 17 February 2020 © Springer-Verlag GmbH Austria, part of Springer Nature 2020

Abstract

Herein, we present a new variation for an eco-friendly methodology for the synthesis of chalcogenoester in good-to-excellent yields in a short time, with an easy work-up/purification step, and in a greenest methodology, affording the minimum generation of solid and liquid waste, in comparison to that described in the literature. Additionally, some selected compounds were evaluated as antimicrobial agents, showing moderate activity against a variety of microorganisms including the *K. pneumoniae*, *P. aeruginosa* and also some selected fish pathogenic bacteria.

Graphic abstract



Keywords Thermal diastereomerization · Photochemistry · Acidity · Fluorescence · Absorption

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00706-020-02565-x) contains supplementary material, which is available to authorized users.

Oscar E. D. Rodrigues rodriguesoed@gmail.com

- ¹ Departamento de Química, Universidade Federal de Santa Maria, Prédio 18, Santa Maria, RS 97105-900, Brazil
- ² Departamento de Fisiologia e Farmacologia, Universidade Federal de Santa Maria-UFSM, CCS, Santa Maria, Rio Grande do Sul 97105-900, Brazil
- ³ Departamento de Química, Universidade Federal da Fronteira Sul, Realeza, PR 85770-000, Brazil
- ⁴ Departamento de Microbiologia, Universidade Franciscana, Santa Maria, RS 97010-032, Brazil

Introduction

Organochalcogen chemistry has been gaining considerable attention due to a high number of publications involving this class of compounds in different scientific fields, including those of biochemistry [1, 2], chemistry [3] and materials [4]. Since chalcogen atoms have an important hole in oxidation processes due to their chemical properties, as well as they are present in the structure of some enzymes [5, 6], they are often reported as a glutathione peroxidase mimic [7–9] even as antitumor agents [10-14]. Regarding organochalcogen compounds, chalcogenoesters offer a wide variety of applications. In organic synthesis, they have been used as a precursor of the acyl radical [15] and acyl anions [16] as well as in the synthesis of new materials, such as molecular conductors and superconductors [17], molecular machines [18, 19], V-shaped materials [20], and liquid crystals [21, 22]. Considering the wide applications of chalcogenoesters, recently, there was an increase in the development of new and effective methodologies providing the desired products. Thereby, there is a large number of protocols for synthesis of chalcogenoesters based on metals including palladium complexes [23], samarium [24], indium [25], mercury [26], bimetallic systems [27], and zinc [28]. However, despite some protocols proved to be highly efficient, they require a conventional purification step, which generally employs a large volume of solvents and silica gel which are normally discarded.

Therefore, research on the development of methodologies that enhance the environment-friendly nature of chemical processes is currently a subject of great interest, mainly in synthetic organic chemistry [29, 30]. In this intend, the preparation of chalcogenoesters using a greener approach, as using ionic liquids (ILs) or solid-phase reactions has been described in the literature [31, 32]. However, for a real account, all synthetical steps must be considered, including the purification process and the toxicity of chemicals involved. In this context, the *E* factor, which is defined as the real amount of waste produced during a transformation and measured by the total mass of waste according to the mass ratio of the desired product, represents a valuable tool for the evaluation of the laboratory chemical synthesis processes, considering the total amount of residue generated, as shown in Fig. 1 [33, 34].

In what concerns the importance of antimicrobial activity, there were 52.8 Mio. deaths globally in 2010 and infectious diseases were among the main causes. These illnesses are represented primarily by lower respiratory infections (2.8 Mio.), neonatal disorders (2.2 Mio.), diarrheal disease (1.4 Mio.), tuberculosis (1.2 Mio.), measles (0.13 Mio.), and tetanus (0.06 Mio.) [35]. In the beginning of this decade, Enterobacteriaceae, which produces Klebsiella pneumoniae carbapenemase (KPC), was reported in the USA and subsequently worldwide. These KPC-producing bacteria are predominantly involved in systemic and nosocomial infections [36]. The emergence of these multi-drug-resistant bacteria is, therefore, of concern, since antimicrobial treatment options are very restricted, because this enzyme leads to decreased susceptibility or even resistance to virtually all β-lactam drugs [37]. The few therapeutic options available are limited to the polymyxins, which are drugs with high nephro and neurotoxic potential [38]. Another microorganism of high clinical importance is Pseudomonas aeruginosa, which is one of the leading nosocomial pathogens. The increasing frequency of multi-drug-resistant P. aeruginosa strains severely limits the number of effective antimicrobials against infections caused by this pathogen [39]. These are the only two examples of the



current critical situation that most hospitals around the world have been facing.

Additionally, bacterial multi-resistance is also a problem in aquaculture. Intensification in fish production led to an increase in density, generating stress and infectious diseases and consequently, increasing the use of antimicrobial agents [40]. These diseases are mainly caused by Gram-negative bacteria, such as Aeromonas hydrophila, A. veronii [41], and Citrobacter freundii [42]. As well as Raoltella ornithinolytica is a Gram-negative bacillus that produces histamines, which leads to poisoning by ingestion of contaminated fish [43]. Overuse of antimicrobials led to an increase of bacterial resistance, residues in the aquatic environment and in the fish meat, generating a public health problem [44]. With increasingly resistant microorganisms coupled with limited therapeutic options, it is essential that research studies aim at the development of new classes of antimicrobial drugs, especially to combat resistant microorganisms.

Therefore, we report a new variant of a low-cost and highly eco-friendly methodology for the synthesis of chalcogenoesters. The desired esters were obtained in good-toexcellent yields in a short reaction time, with an easy workup/purification step and a lower E factor, compared with similar protocols (Fig. 2).

The antimicrobial activity of the compounds obtained against Gram-positive and Gram-negative bacteria, including *K. pneumoniae*, *P. aeruginosa* and fish pathogenic bacteria was investigated. It should be noted that the present protocol represents a 'greener' variant aimed at improving a traditional methodology for the preparation of chalcogenoesters and consists of a simple molecular building blocks for new antimicrobial compounds.

Results and discussion

Synthesis of the chalcogenoesters

To synthesize the chalcogenoesters, diphenyl diselenide was diluted in acetone followed by the addition of four



Fig. 2 General synthesis scheme

equivalents of zinc dust (Zn^{0}) as the reducing agent and 1 cm³ of hydrochloric acid (HCl) 1 M. After 5 min, a complete disappearance of the yellow coloration was observed, indicating total reduction of diselenide. p-toluoyl acyl chloride was then added and the reaction was monitored by thinlayer chromatography (TLC). After 30 min, a precipitate was visible and the consumption of the starting material was confirmed by TLC. Aiming at the development of a 'green' work-up, 5 cm³ of 0.1 M HCl was added to the reaction vessel, forcing the precipitation of the desired product. A filtration under vacuum was then carried out, leading to a mixture of the desired product and metallic zinc. Subsequently, the residual selenol was removed by the HCl solution, avoiding the oxidation of selenol in the presence of the product. The mixture with the chalcogenoester and zinc was finally diluted in acetone and filtered. The solvent was removed under vacuum, affording the pure product. To evaluate the scope of the methodology, a variety of dichalcogenides containing electron-withdrawing and donating groups as well as different acyl chlorides were employed. The results are summarized in Table 2.

The synthesized chalcogenoesters were obtained in goodto-excellent yields, with selenium species providing the respective compounds in better yields comparing to those bearing the sulfur moiety. This result is probably due to the higher nucleophilicity of the selenium atom (Se) compared with sulfur (S). The influence of the substituent attached to the aromatic ring of the acyl chloride was also studied. In a general view, the protocol was not sensible to electronic effects (Table 1, compounds 1-4) with a slight decrease in the yield observed in compound 4 when *t*-Bu group in para position was employed (Table 1, compound 4). Furthermore, the influence by groups attached to the aromatic ring of selenium moiety was investigated. It was possible to observe that strong electron-donating groups affect the dichalcogenide cleavage step. For instance, compound **5** required the longest time to allow the cleavage of dichalcogenium bond comparing to other substituted diselenides, probably due to Se–Se

Table 2 Values of minimal inhibitory concentration of compounds 1, 2, 6, 9, and 10 in mg/cm^3

Compound	Gram-posi rial strains	tive bacte-	Gram-negative bacterial strains			
	S. aureus	L. mono- cytogenes	K. pneumoniae	P. aeruginosa		
1	1.17	0.58	0.58	0.58		
2	0.58	0.58	-	0.29		
6	-	-	0.58	_		
9	_	0.58	-	0.58		
10	-	1.17	-	1.17		

				RYAr						
Entry	Comp	R	Ar	Y	Reagents	Waste	Product	E factor	Yield/% ^a	References
1	1	4-Me-C ₆ H ₄	C ₆ H ₅	Se	3.65	3.38	0.264	12.82	96	[47]
2	2	$4-NO_2-C_6H_4$	C ₆ H ₅	Se	3.68	3.39	0.290	11,68	95	[25]
3	3	$2-Cl-C_6H_4$	C ₆ H ₅	Se	3.67	3.37	0,292	11.56	99	[48]
4	4	4-t-Bu-C ₆ H ₄	C ₆ H ₅	Se	3.69	3.44	0.250	13.76	79	[48]
5	5 ^b	4-Me-C ₆ H ₄	2-OMe-C ₆ H ₄	Se	3.68	3.41	0.271	12.58	89	-
6	6	4-Me-C ₆ H ₄	4-Me-C ₆ H ₄	Se	3.66	3.38	0.280	12.07	97	[49]
7	7	4-Me-C ₆ H ₄	$4-Cl-C_6H_4$	Se	3.68	3.38	0.294	11.51	95	[47]
8	8	$4-NO_2-C_6H_4$	C ₆ H ₅	S	3.63	3.39	0.233	14.55	90	[50]
9	9	4-Me-C ₆ H ₄	$4-Cl-C_6H_4$	S	3.63	3.41	0.218	15.65	83	[51]
10	10	$4-NO_2-C_6H_4$	$4-Cl-C_6H_4$	S	3.67	3.40	0.270	12.60	92	[52]
11	11	$4-NO_2-C_6H_4$	4-OMe-C ₆ H ₄	S	3.66	3.41	0.245	13.94	85	-
12	12	$2-Cl-C_6H_4$	$4-Cl-C_6H_4$	S	3.65	3.43	0.223	15.38	79	-
13 ^c	12	$2-Cl-C_6H_4$	$4-Cl-C_6H_4$	S	182.56	182.34	0.223	817.67	79	

Table 1 Results obtained for the chalcogenoester-synthesized 1–12

^aProduct isolated direct from the reaction and characterized by ¹H NMR, ¹³C NMR, and CG/MS

^bRequired 20 min to cleave the diselenide

^cComparative result of entry 12 using conventional column purification/extraction step. Extraction with 50 cm³ CH₂Cl₂ (66.5 g); column using 10 g of silica flash and 150 cm³ of solution 10% ethyl acetate (13.45 g) in *n*-hexane (88.96 g)

bond strengthening by the presence of the electron-donating group.

To verify the scope of the methodology concerning the chalcogenium source, experiments were carried out using different species of disulfides and the results are summarized in Table 1 (compounds 8-12). In general, disulfides showed comparable behavior as diselenides in terms of reactivity with different acyl chlorides and without a deep variation comparing the electronic effects of the substituents attached to aromatic ring in the disulfide moiety.

The E-factor calculations for laboratorial reactions could afford an interesting panorama about the greenest way developed in the synthetical protocols. Based on the experimental procedure, it was possible to calculate the E factor of the described methodology. In this context, an arithmetic average was calculated to the methodology using Fig. 1. As a result, it was obtained a medium E-factor total corresponding to the synthesis, extraction and purification. For a comparative analysis, an extraction and purification steps were introduced in the methodology (Table 1, entry 13) for the highest E factor obtained, related to entry 12. Using a conventional extraction with 50 cm³ of CH₂Cl₂ and a traditional purification employing 10 g of silica flash and 150 cm³ of a mixture of ethyl acetate and *n*-hexane (10%), the *E* factor of this example increased from 15.38 to 817.67, showing how greenest this methodology is in the synthesis of chalcogenoesters (see supplementary data).

Biological activity

Minimal inhibitory concentration (MIC) of compounds 1, 2, 6, 9, and 10 against Gram-positive (*Staphylococcus aureus* and *Listeria monocytogenes*) and Gram-negative (*K. pneumoniae* and *P. aeruginosa*) bacterial strains

The evaluation of the antibacterial activity of compounds **1**, **2**, **6**, **9**, and **10** was performed through the technique of micro-dilution, in which the MIC of the tested compounds can be observed against Gram-positive (*S. aureus* and *L. monocytogenes*) and Gram-negative (*K. pneumoniae* and *P. aeruginosa*) bacterial strains (Table 2).

Interestingly, the respective chalcogenoesters showed a modulation in the antimicrobial activity according to the groups present in the molecules. For instance, a broad activity against all strains was observed for compound **1**, while a very selective activity was observed for compound **6** which was proved active only against *K. pneumoniae*. This result increases the interest for clinical application of these chalcogenoesters, because either a broad spectrum of action or a selective activity is highly desirable depending on the type of infection observed. When some antimicrobial treatment is performed based on the results of antimicrobial susceptibility testing, the treatment with narrow-spectrum drugs is advantageous for preventing the activity of the drug against beneficial microorganisms of the normal microbiota. However, in most cases, depending on the severity of the infection, it is not possible to establish the causal agent. In these cases, the use of narrow-spectrum drugs is not appropriate, and the availability of broad-spectrum drugs is fundamental.

Minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) of compounds 1 and 2 against fish pathogenic bacteria

Based on the results shown above, compounds **1** and **2** were tested against fish pathogenic bacteria (Table 3). The bacteria tested and their ascension numbers in GenBank were: *A. hydrophila* (MF372509), *A. hydrophila* (MF372510), *A. veronii* (MF372508), *C. freundii* (MF565839) and *R. orni-thinolytica* (MF372511).

Compound **1** showed good bacteriostatic and bactericidal activity against strains of the genus *Aeromonas* and moderate activity against the other strains. Compound **2** showed moderate bacteriostatic activity and weak bactericidal activity against bacteria isolated from fish.

Florfenicol and oxytetracycline are approved by the Food and Drug Administration (FDA) for use in aquaculture [45]. These two conventional antimicrobials were tested against the strains *A. hydrophila* (MF372510), *C. freundii* (MF565839), and *R. ornithinolytica* (MF372511) in a previous study under the same experimental conditions. In this study, the florfenicol MIC values were 1.01 μ g/cm³ for *A. hydrophila* strain and 8.13 μ g/cm³ for *C. freundii* and *R. ornithinolytica* strains. In addition, the oxytetracycline MIC values were 0.51 μ g/cm³ for *A. hydrophila* strain and 4.06 μ g/cm³ for *C. freundii* and *R. ornithinolytica* strains [46].

Table 3MIC and MBC valuesof compounds 1 and 2, againstfish-isolated bacterial strains inmg/cm3

Comp	A. hydrophila MF372509		A. hydrophila MF372510		A. veronii MF372508		C. freundii MF565839		<i>R. ornithinolyt-ica</i> MF372511	
	MIC	MBC	MIC	MBC	MIC	MBC	MIC	MBC	MIC	MBC
1	0.65	0.65	0.65	0.65	1.3	1.3	2.6	2.6	2.6	2.6
2	2.3	2.3	2.3	2.3	2.3	4.6	2.3	>4.6	4.6	>4.6

Conclusions

In summary, a new methodology for the 'greener' synthesis of chalcogenoesters was developed. Following an easy, clean and not expensive synthetical protocol, 12 chalcogenoesters were obtained in good-to-excellent yields, in short reaction times and employing a low toxicity metal as the reducing agent. Among them, chromatographic purification methods are not required, eliminating the use of a large amount of solvents affording low waste generation and leading to an appreciably low *E*-factor value. In addition, the synthesized compounds showed an antimicrobial activity, notably on clinically important microorganisms and also against fish pathogenic bacterial strains. Consequently, these chalcogenoesters open up possibilities for the development of new small molecular architectures for antimicrobial activity.

Experimental

General procedure for the synthesis of chalcogenoesters 1–12

In a Schlenck tube under argon atmosphere was added 2 mmol of zinc dust, $(ArY)_2$ (0.5 mmol), 1 cm³ acetone, and 0.75 cm³ of HCl (1 M) in this sequence. The mixture was stirred until complete disappearance of coloration and then acyl chloride (1.0 mmol) was added. The reaction was stirred during 30 min at room temperature. Then, 5 cm³ HCl (0.1 M) was added and the reaction mixture was quickly filtrated under vacuum. The mixture between Zn⁰ and chalcogenoester was transferred to an Erlenmeyer flask and 3 cm³ acetone was added. After solubilizing the entire product, a new filtration was performed to separate the product and zinc dust. The solution was evaporated under reduced pressure and the desired product dried in vacuum pump. The NMR data and spectra of all compounds are available in the Supplementary Material.

Se-(2-Methoxyphenyl) 4-methylbenzoselenoate (5, $C_{15}H_{14}O_2Se$) Yield: 89%; ¹H NMR (400 MHz, CDCl₃): δ =7.58 (d, *J*=8.07 Hz, 2H), 7.60 (m, 1H), 7.42 (td, *J*=7.58, 1.51 Hz, 1H), 7.25 (d, *J*=8.07 Hz, 2H), 7.00 (m, 2H) ppm; ¹³C NMR (100 MHz, CDCl₃): δ =191.9, 159.2, 144.6, 138.3, 136.0, 131.2, 129.4, 127.4, 121.4, 114.8, 111.2, 56.0, 21.7 ppm.

S-(4-Methoxyphenyl) 4-nitrobenzothioate (11, $C_{14}H_{11}NO_4S$) Yield: 85%; ¹H NMR (400 MHz, CDCl₃): δ =8.33 (d, J=8.8 Hz, 2H), 8.16 (d, J=8.80 Hz, 2H), 7.42 (d, J=8.80 Hz, 2H), 7.02 (d, J=8.80 Hz, 2H), 3.85 (s, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃): *δ* = 189.9, 161.6, 151.0, 141.8, 136.7, 128.7, 124.2, 117.1, 115.5, 55.7 ppm.

S-(4-Chlorophenyl) 2-chlorobenzothioate (12, $C_{13}H_8Cl_2OS$) Yield: 79%; ¹H NMR (400 MHz, CDCl₃): δ=7.75 (dd, J=7.58, 1.22 Hz, 1H), 7.50–7.41 (m, 6H), 7,36 (td, J=7.58, 1.71 Hz) ppm; ¹³C NMR (100 MHz, CDCl₃): δ=189.5, 136.7, 136.2, 135.9, 132.6, 130.9, 129.6, 129.1, 126.8, 126.6, 125.9 ppm.

Microorganisms

For the evaluation of the biological activity of the chalcogenoesters prepared, compounds **1**, **2**, **6**, **9**, and **10** were tested for their efficacy as antibacterial agents against Gram-positive (*Staphylococcus aureus* and *Listeria monocytogenes*) and Gram-negative (*K. pneumoniae* and *P. aeruginosa*) bacterial strains, expressed through MIC (minimal inhibitory concentration). Also, MIC and MBC (minimal bactericidal concentration) assays were performed against fish pathogenic bacteria, their ascension numbers in GenBank were *A. hydrophila* (MF372509), *A. hydrophila* (MF372510), *A. veronii* (MF372508), *C. freundii* (MF565839), and *R. ornithinolytica* (MF372511).

Antibacterial activity

The antibacterial activity of chalcogenoesters 1, 2, 6, 9, and 10 was determined by the minimal inhibitory concentration (MIC) according to the Clinical and Laboratory Standards Institute (CLSI) (Wayne, 2009). The MIC was determined by micro-dilution technique in Mueller-Hinton broth (Difco). The assay was carried out in 96-well microtitre plates. In each well with Müller-Hinton broth was placed an inoculum prepared in the same medium at a density adjusted per tube to 0.5 of the McFarland scale $(1.5 \times 10^8 \text{ CFU/cm}^3)$ with sterile saline and lastly placed different concentrations of chalcogenoesters performed in triplicate. Microtiter trays were incubated at 37 °C and the MICs were recorded after 24 h of incubation. There was bacterial growth in the wells selected as positive growth and no bacterial growth was observed in the wells that did not receive the inoculums (negative controls-DMSO). The MIC was defined as the lowest concentration of compound that inhibits microbial growth. The tests to evaluate the antibacterial activity (MIC) and minimal bactericidal concentration (MBC) of compounds 1 and 2 against fish pathogenic bacteria were performed according to CLSI specific for these microorganisms (Wayne 2014) and at 28 °C. Values of MBC were confirmed by re-inoculation of 10 mm³ of each bacterial culture on Mueller-Hinton Agar (28 °C/24 h), and the lowest concentration of the substances showing no growth was defined as the MBC.

Acknowledgements The authors gratefully acknowledge CAPES-Finance Code 001, CAPES PRINT-NANOMATERIAIS, CAPES-PROEX, CAPES-PRINT, CNPq (Ed. Universal 400791/2016-1, Produtividade em Pesquisa 303387/2015-7, 306240/2018-1 Pesquisador Visitante-401397/2014-9) for financial support.

References

- Flohé L, Anderseen JR, Brigelius-Flohé R, Maiorino M, Ursini F (2000) IUBMB Life 49:411
- 2. Cristina CW, Zeni G, Rocha JBT (2004) Chem Rev 104:6255
- Boger DL, Mathvink RJ (1992) J Org Chem 57:1429
 Mahmudov KT, Kopylovich MN, da Silva MFCG, Pombeiro AJL
- (2017) Dalton Trans 46:10121
- Jacob C, Giles GI, Giles NM, Sies H (2003) Angew Chem Int Ed 42:4742
- 6. Sarma BK, Mugesh G (2008) Org Biomol Chem 6:965
- Rotruck JT, Pope AL, Ganther HE, Swanson AB, Hafeman DG, Hoekstra WG (1973) Science 179:588
- 8. Mugesh G, Singh HB (2000) Chem Soc Rev 29:347
- 9. Jiao JA, Yang N, Wang J, Xu X, Jin Z (2013) J Incl Phenom Macro 75:155
- 10. Zhao L, Li J, Li Y, Li J, Wirth T, Li Z (2012) Bioorg Med Chem 20:2558
- De Souza D, Mariano DOC, Nedel F, Schultze E, Campos VF, Seixas F, Da Silva RS, Munchen TS, Ilha V, Dornelles L, Braga AL, Rocha JBT, Collares T, Rodrigues OED (2015) J Med Chem 58:3329
- Da Rosa RM, Piccoli BC, Da Silva FD, Dornelles L, Da Rocha JBT, Sonego MS, Begnini KR, Collares T, Seixas FK, Rodrigues OED (2016) Med Chem Commun 8:408
- Munchen TS, Sonego MS, De Souza D, Dornelles L, Seixas FK, Collares T, Piccoli CB, Da Silva FD, Da Rocha JBT, Quoos N, Rodrigues OED (2018) Chem Select 3:3479
- Tabarelli G, Dornelles L, Iglesias BA, Gonçalves DF, Stefanello ST, Soares FAA, Piccoli BC, Da Silva FD, Da Rocha JBT, Schultze E, Bender CB, Collares T, Seixas KF, Peterle MM, Braga AL, Rodrigues OED (2017) Chem Select 2:8423
- 15. Chen C, Crish D, Papadotos A (1992) J Am Chem Soc 114:8313
- Hiiro T, Morita Y, Inoue T, Kambe N, Ogawa A, Ryu I, Sonoda N (1990) J Am Chem Soc 112:455
- 17. Yamada J, Akutsu H, Nishikawa H, Kikuchi K (2004) Chem Rev 104:5057
- Balzani V, Credi A, Rayamo FM, Stoddart JF (2000) Angew Chem Int Ed 39:3348
- Kan Y, Tso KC, Chan SL, Guan X, Che C (2013) New J Chem 37:1811
- Rodrigo R, Westphal E, Bechtold IH, Bortoluzzi AJ, Gallardo H (2007) Tetrahedron 63:2851
- 21. Woon KL, Aldred MP, Vlachos P, Mehl GH, Stirner T, Kelly SM, O'Neil M (2006) Chem Mater 18:2311
- Rampon DS, Rodembusch FS, Schneider JMFM, Bechtold IH, Gonçalves PFB, Merlo AA, Schneider PH (2010) J Mater Chem 20:715
- 23. Nishiyama Y, Kawamatsu H, Funato S, Tokunaga K, Sonoda M (2003) J Org Chem 68:3599
- 24. Chena R, Zhang Y (2000) Synth Commun 30:1331
- Marin G, Braga AL, Rosa AS, Galetto FZ, Burrow RA, Gallardo H, Paixão MW (2009) Tetrahedron 65:4614
- Silveira CC, Braga AL, Larghi EL (1999) Organometallics 18:5183
- 27. Nishyama Y, Tokunaga T, Kawamatsu H, Sonoda N (2002) Tetrahedron Lett 43:1507

- Godoi M, Galetto FZ, Botteselle GV, Ricardo EW, Braga AL (2012) Green Chem 14:456
- 29. Horváth IT, Anastas P (2007) Chem Rev 107:2167
- 30. Horváth IT, Anastas PT (2007) Chem Rev 107:2169
- Narayanaperumal S, Alberto EE, Gul K, Kawazoko CY, Dornelles L, Rodrigues OED, Braga AL (2011) Tetrahedron 67:4723
- 32. Ghassemian A, Vila-Férres X, Alenwood PF, Durek T (2013) Bioorg Med Chem 21:3473
- 33. Dunn PJ, Galvin S, Hettenbach K (2004) Green Chem 6:43
- Martins MAP, Frizzo CP, Moreira DN, Buriol L, Machado P (2009) Chem Rev 109:4140
- 35. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarval R, Anh SY, AlMazroa M, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels TH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Abdulhak AB, Birbeck G, Blyth F, Bolliger I, Boufus S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Coulson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala M, De Leo D, Desenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feijin V, Flaxman AD, Forouzanfar MH, Fowkes FGR, Frankiln R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzales-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S. Johns S. Karthikevan G. Kassebaum N. Keren A. Khoo J-P, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, McIntire MF, Mollinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Memish GA, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Moklad AA, Moran A, Mulholland K, Nair NM, Naldi M, Narayan KMV, Nasseri K, Norman P, O'Donnel M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JD, Rein DB, Remuzzi G, Rivara FP, Roberts T, De Léon FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh P-H, Yip P, Zabetian A, Zheng Z-J, Lopez AD, Murray CJL (2012) Lancet 380:2095
- Dolejska M, Villa L, Poirel L, Nordmann P, Carattoli A (2013) J Antimicrob Chemother 68:34
- 37. Worthington RJ, Melander C (2013) J Org Chem 78:4207
- 38. Mendes CAC, Burdmann EA (2010) Rev Assoc Med Bras 56:752
- 39. Nordmann P, Cuzon G, Naas T (2009) Lancet Infect Dis 9:228
- Watts JEM, Schreier HJ, Lanska L, Hale MS (2017) Mar Drugs 15:158
- Ghatak S, Blom J, Das S, Sanjukta R, Kekungu P, Mawlong M, Shakuntala I, Sen A, Goesmann A, Kumar A, Ngachan SV (2016) Antonie Van Leeuwenhoek 109:945
- Pádua SB, Marques DP, Sebastião FA, Pilarski F, Martins ML, Ishikawa MM (2014) Braz J Vet Pathol 7:151
- 43. Kanki M, Yoda T, Tsukamoto T, Shibata T (2002) Appl Environ Microbiol 68:3462
- 44. Cabello FC (2006) Environ Microbiol 8:1137
- FDA (2014) Approved drugs. Food and Drug Administration— Department of Health and Human Services, Silver Spring

- Bandeira JG, Sutili FJ, Gressler LT, Ely VL, Silveira BP, Tasca C, Reghelin M, Matter LB, Vargas APC, Baldisserotto B (2018) J Appl Microbiol 125:655
- 47. Ishihara H, Matsunami N, Yamada Y (1987) Synthesis 4:371
- 48. Nishiyama Y, Katsuura A, Negoro A, Hamanaka S, Miyoshi N, Yamana Y, Ogawa A, Sonoda N (1991) J Org Chem 56:3776
- 49. Kimura M, Iwata A, Itoh M, Yamada K, Kimura T, Sugiura N, Ishida M, Kato S (2006) Helv Chim Acta 89:747
- 50. Dan W, Deng H, Chen J, Ding J, Wu H (2010) Tetrahedron 66:7384
- 51. Zeng J-W, Liu Y-C, Hsieh P-A, Huang Y-T, Yi C-L, Badsara SS, Lee C-F (2014) Green Chem 16:2644
- 52. Feng J, Lv M-F, Lu G-P, Cai C (2015) Org Biomol Chem 13:677

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.